Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794695 | 0.89 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SHBGESR1 | |
| SCHEMBL6801524 | 0.85 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SHBGESR1 | |
| SCHEMBL6797675 | 0.83 | SHBG (0.44) | OPRM1OPRD1OPRK1SHBGESR1 | |
| SCHEMBL6795255 | 0.78 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SHBGESR1 | |
| SCHEMBL6794061 | 0.78 | OPRM1 (0.37) | OPRM1OPRD1OPRK1ESR1ESR2 | |
| SCHEMBL6798125 | 0.73 | ESR1 (0.39) | OPRM1SHBGESR1ESR2 | |
| SCHEMBL6800364 | 0.73 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL6800177 | 0.71 | ESR2 (0.38) | OPRD1ESR1ESR2 | |
| SCHEMBL6800542 | 0.71 | DYRK1A (0.35) | OPRM1OPRD1OPRK1ESR1ESR2 | |
| SCHEMBL7073179 | 0.70 | ESR1 (0.38) | OPRM1OPRD1OPRK1SHBGESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | claimed |
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1339662-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002046134-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | OPRM1 1180/4885OPRD1 463/4885OPRK1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.